NO991569L - Liquid alendronate compounds - Google Patents
- ️Fri Jun 04 1999
NO991569L - Liquid alendronate compounds - Google Patents
Liquid alendronate compoundsInfo
-
Publication number
- NO991569L NO991569L NO991569A NO991569A NO991569L NO 991569 L NO991569 L NO 991569L NO 991569 A NO991569 A NO 991569A NO 991569 A NO991569 A NO 991569A NO 991569 L NO991569 L NO 991569L Authority
- NO
- Norway Prior art keywords
- liquid
- compounds
- preparation
- liquid alendronate
- alendronate compounds Prior art date
- 1996-10-04
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Flytende preparat av alendronsyre eller et farmasøytisk akseptabelt salt som har nok buffer, slik at pH i preparatet er 4-7,5, og 15 ml av preparatet har evnen til å heve pH i 50 ml 0,1 N HC1 fra l til minst 3, og fortrinnsvis 4.Liquid preparation of alendronic acid or a pharmaceutically acceptable salt having sufficient buffer, so that the pH of the preparation is 4-7.5, and 15 ml of the preparation has the ability to raise the pH in 50 ml of 0.1 N HCl from 1 to at least 3 , and preferably 4.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2676596P | 1996-10-04 | 1996-10-04 | |
| GBGB9700541.7A GB9700541D0 (en) | 1997-01-13 | 1997-01-13 | Liquid alendronate formulation |
| US3600297P | 1997-01-22 | 1997-01-22 | |
| PCT/US1997/015740 WO1998014196A1 (en) | 1996-10-04 | 1997-10-02 | Liquid alendronate formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991569D0 NO991569D0 (en) | 1999-03-30 |
| NO991569L true NO991569L (en) | 1999-06-04 |
Family
ID=27268667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991569A NO991569L (en) | 1996-10-04 | 1999-03-30 | Liquid alendronate compounds |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1007054A4 (en) |
| JP (1) | JP2001501222A (en) |
| CN (1) | CN1238691A (en) |
| AU (1) | AU723357B2 (en) |
| BG (1) | BG103306A (en) |
| BR (1) | BR9712197A (en) |
| CA (1) | CA2267370A1 (en) |
| CZ (1) | CZ116999A3 (en) |
| EA (1) | EA001213B1 (en) |
| EE (1) | EE03669B1 (en) |
| HU (1) | HUP0000125A3 (en) |
| IL (1) | IL129127A0 (en) |
| IS (1) | IS5012A (en) |
| NO (1) | NO991569L (en) |
| NZ (1) | NZ334836A (en) |
| PL (1) | PL332496A1 (en) |
| SK (1) | SK42999A3 (en) |
| TR (1) | TR199900730T2 (en) |
| WO (1) | WO1998014196A1 (en) |
| YU (1) | YU17499A (en) |
Families Citing this family (11)
* Cited by examiner, † Cited by third party| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560490B2 (en) * | 2001-01-23 | 2009-07-14 | Gador S.A. | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof |
| US7645460B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of risedronate |
| US7645459B2 (en) | 2004-05-24 | 2010-01-12 | The Procter & Gamble Company | Dosage forms of bisphosphonates |
| US20080286359A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| US20080287400A1 (en) | 2004-05-24 | 2008-11-20 | Richard John Dansereau | Low Dosage Forms Of Risedronate Or Its Salts |
| JP2009508834A (en) * | 2005-09-16 | 2009-03-05 | セラマイン リミテッド | Bisphosphonate formulation |
| US7473684B2 (en) | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
| JP2010043119A (en) * | 2009-10-16 | 2010-02-25 | Gador Sa | Composition for preventing and/or treating bone metabolic disease, method of preparing the same and use thereof |
| US8568747B1 (en) | 2012-10-05 | 2013-10-29 | Silvergate Pharmaceuticals, Inc. | Enalapril compositions |
| US9463183B1 (en) | 2015-10-30 | 2016-10-11 | Silvergate Pharmaceuticals, Inc. | Lisinopril formulations |
| US9669008B1 (en) | 2016-03-18 | 2017-06-06 | Silvergate Pharmaceuticals, Inc. | Enalapril formulations |
Family Cites Families (11)
* Cited by examiner, † Cited by third party| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4206209A (en) * | 1978-11-02 | 1980-06-03 | Kracauer Paul | Sublingual aspirin tablet |
| IT1201087B (en) * | 1982-04-15 | 1989-01-27 | Gentili Ist Spa | PHARMACOLOGICALLY ACTIVE BIPPHOSPHONES, PROCEDURE FOR THEIR PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS |
| US4922007A (en) * | 1989-06-09 | 1990-05-01 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof |
| US5019651A (en) * | 1990-06-20 | 1991-05-28 | Merck & Co., Inc. | Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof |
| US5270365A (en) * | 1991-12-17 | 1993-12-14 | Merck & Co., Inc. | Prevention and treatment of periodontal disease with alendronate |
| US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
| FR2703590B1 (en) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | USE OF BISPHOSPHONIC ACID DERIVATIVES FOR THE PREPARATION OF MEDICINES FOR PROMOTING BONE REPAIR. |
| US5510517A (en) * | 1993-08-25 | 1996-04-23 | Merck & Co., Inc. | Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids |
| US5462932A (en) * | 1994-05-17 | 1995-10-31 | Merck & Co., Inc. | Oral liquid alendronate formulations |
| US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
| US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
-
1997
- 1997-10-02 BR BR9712197-5A patent/BR9712197A/en unknown
- 1997-10-02 CA CA002267370A patent/CA2267370A1/en not_active Abandoned
- 1997-10-02 EE EEP199900113A patent/EE03669B1/en not_active IP Right Cessation
- 1997-10-02 IL IL12912797A patent/IL129127A0/en unknown
- 1997-10-02 EP EP97945195A patent/EP1007054A4/en not_active Withdrawn
- 1997-10-02 EA EA199900352A patent/EA001213B1/en not_active IP Right Cessation
- 1997-10-02 NZ NZ334836A patent/NZ334836A/en unknown
- 1997-10-02 WO PCT/US1997/015740 patent/WO1998014196A1/en not_active Application Discontinuation
- 1997-10-02 CN CN97180165A patent/CN1238691A/en active Pending
- 1997-10-02 SK SK429-99A patent/SK42999A3/en unknown
- 1997-10-02 CZ CZ991169A patent/CZ116999A3/en unknown
- 1997-10-02 HU HU0000125A patent/HUP0000125A3/en unknown
- 1997-10-02 PL PL97332496A patent/PL332496A1/en unknown
- 1997-10-02 AU AU46448/97A patent/AU723357B2/en not_active Ceased
- 1997-10-02 JP JP10516541A patent/JP2001501222A/en active Pending
- 1997-10-02 TR TR1999/00730T patent/TR199900730T2/en unknown
-
1999
- 1999-03-26 IS IS5012A patent/IS5012A/en unknown
- 1999-03-30 NO NO991569A patent/NO991569L/en not_active Application Discontinuation
- 1999-03-31 YU YU17499A patent/YU17499A/en unknown
- 1999-04-02 BG BG103306A patent/BG103306A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL332496A1 (en) | 1999-09-13 |
| CA2267370A1 (en) | 1998-04-09 |
| IL129127A0 (en) | 2000-02-17 |
| AU4644897A (en) | 1998-04-24 |
| AU723357B2 (en) | 2000-08-24 |
| SK42999A3 (en) | 2000-01-18 |
| HUP0000125A3 (en) | 2001-04-28 |
| CZ116999A3 (en) | 1999-09-15 |
| TR199900730T2 (en) | 1999-07-21 |
| EP1007054A4 (en) | 2000-07-19 |
| YU17499A (en) | 1999-11-22 |
| EA001213B1 (en) | 2000-12-25 |
| EE9900113A (en) | 1999-10-15 |
| BG103306A (en) | 2000-01-31 |
| EA199900352A1 (en) | 1999-08-26 |
| CN1238691A (en) | 1999-12-15 |
| EP1007054A1 (en) | 2000-06-14 |
| WO1998014196A1 (en) | 1998-04-09 |
| IS5012A (en) | 1999-03-26 |
| BR9712197A (en) | 1999-08-31 |
| EE03669B1 (en) | 2002-04-15 |
| JP2001501222A (en) | 2001-01-30 |
| NZ334836A (en) | 2000-11-24 |
| NO991569D0 (en) | 1999-03-30 |
| HUP0000125A2 (en) | 2000-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991569L (en) | 1999-06-04 | Liquid alendronate compounds |
| NO943888L (en) | 1995-04-18 | Pharmaceutical preparation |
| NO20052335L (en) | 2005-07-15 | Dispersible deferacirox tablets |
| MY154010A (en) | 2015-04-30 | Rapidly disintegrable solid preparation |
| DK0850046T3 (en) | 2003-03-03 | Microemulsions for use as vehicle for administration of active compounds |
| BG104476A (en) | 2000-12-29 | Therapeutical form for tolterodin with controlled release |
| NO952863D0 (en) | 1995-07-19 | Fluoxetine Pharmaceutical Compositions |
| HUP0101439A2 (en) | 2001-10-28 | Sustained-release preparation for a ii antagonist, production and use thereof |
| CA2213996A1 (en) | 1997-07-17 | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate |
| NO20032773D0 (en) | 2003-06-18 | Pharmaceutical preparation comprising pyrsazolo [4,3-d] pyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| NO20024733D0 (en) | 2002-10-02 | Hydrophilic molecular dispersion solutions of carvedilol |
| SE0101379D0 (en) | 2001-04-18 | Composition that inhibits gastric acid secretion |
| DK0637236T3 (en) | 1997-03-17 | Pharmaceutical composition and process for its preparation |
| NO994431L (en) | 1999-09-13 | New wording |
| PT1425005E (en) | 2006-09-29 | PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS LUMIRACOXIB |
| RS50089B (en) | 2009-01-22 | Ziprasidone suspension |
| CA2503154A1 (en) | 2004-05-06 | A new crystalline form of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid |
| ATE201680T1 (en) | 2001-06-15 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE ACID ADDITION SALTS |
| HUP9900227A2 (en) | 2000-03-28 | New pharmacological use of aii-receptor antagonists |
| DE59600741D1 (en) | 1998-12-03 | ROD KNOT |
| NZ334949A (en) | 2000-12-22 | Stabilised pharmaceutical composition of quinupristine and dalfopristine with methanesulphonic acid or hydrochloric acid |
| RO115414B1 (en) | 2000-02-28 | Intranasal pharmaceutical composition |
| LV11524A (en) | 1996-10-20 | Use of benzidamine as a treatment for pathological conditions induced by TNF |
| RU99102949A (en) | 2000-12-10 | PREPARATION "ANTIGRIPPIN" |
| MXPA03005441A (en) | 2003-09-10 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 2003-03-03 | FC2A | Withdrawal, rejection or dismissal of laid open patent application |